[1]
Ashwood, V.; Brownhill, V.; Higginbottom, M.; Horwell, D.C.; Hughes, J.; Lewthwaite, R.A. Pd 176252--the first high affinity non-peptide gastrin-releasing peptide (bb2) receptor antagonist. Bioorg. Med. Chem. Lett., 1998, 8(18), 2589-2594.
[2]
Moody, T.W.; Nakagawa, T.; Kang, Y.; Jakowlew, S.; Chan, D.; Jensen, R.T. Bombesin/gastrin-releasing peptide receptor antagonists increase the ability of histone deacetylase inhibitors to reduce lung cancer proliferation. J. Mol. Neurosci., 2006, 28(3), 231-238.
[3]
Moody, T.W.; Leyton, J.; Garcia-Marin, L.; Jensen, R.T. Nonpeptide gastrin releasing peptide receptor antagonists inhibit the proliferation of lung cancer cells. Eur. J. Pharmacol., 2003, 474(1), 21-29.
[4]
Li, X.; Lv, Y.; Yuan, A.; Yi, S.; Ma, Y.; Li, Z. Gastrin-releasing peptide promotes the growth of HEPG2 cells via EGFR-independent ERK1/2 activation. Oncol. Rep., 2010, 24(2), 441-448.
[5]
Zhang, Q.; Bhola, N.E.; Lui, V.W.; Siwak, D.R.; Thomas, S.M.; Gubish, C.T. Antitumor mechanisms of combined gastrin-releasing peptide receptor and epidermal growth factor receptor targeting in head and neck cancer. Mol. Cancer Ther., 2007, 6(4), 1414-1424.
[6]
Thomas, S.M.; Grandis, J.R.; Wentzel, A.L.; Gooding, W.E.; Lui, V.W.; Siegfried, J.M. Gastrin-releasing peptide receptor mediates activation of the epidermal growth factor receptor in lung cancer cells. Neoplasia, 2005, 7(4), 426-431.
[7]
Saito, A.; Yamashita, T.; Mariko, Y.; Nosaka, Y.; Tsuchiya, K.; Ando, T. A synthetic inhibitor of histone deacetylase, ms-27-275, with marked in vivo antitumor activity against human tumors. Proc. Natl. Acad. Sci. USA, 1999, 96(8), 4592-4597.
[8]
Rakesh, K.P.; Wang, S.M.; Jing, L.; Ravindar, L.; Asiri, A.M.; Marwani, H.M. Recent development of sulfonyl or sulfonamide hybrids as potential anticancer agents: A key review. Anticancer. Agents Med. Chem., 2017, 18(4), 488-505.
[9]
Belum, V.R.; Fontanilla, P.H.; Lacouture, M.E.; Rodeck, U. Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol., 2013, 9(8), 1161-1170.
[10]
Belum, V.R.; Washington, C.; Pratilas, C.A.; Sibaud, V.; Boralevi, F.; Lacouture, M.E. Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis. Pediatr. Blood Cancer, 2015, 62(5), 798-806.
[11]
Brannon-Peppas, L.; Blanchette, J.O. Nanoparticle and targeted systems for cancer therapy. Adv. Drug Deliv. Rev., 2012, 56(11), 1649-1659.
[12]
Magalhaes, L.G.; Ferreira, L.; Andricopulo, A.D. Recent advances
and perspectives in cancer drug design. Anais Acad. Brasil. . Ciencias, 2018, 1233-1250.
[13]
Rosen, A.C.; Case, E.C.; Dusza, S.W.; Balagula, Y.; Gordon, J.; West, D.P. Impact of dermatologic adverse events on quality of life in 283 cancer patients: A questionnaire study in a dermatology referral clinic. Am. J. Clin. Dermatol., 2013, 14(4), 327-333.
[14]
Gandhi, M.; Oishi, K.; Zubal, B.; Lacouture, M.E. Unanticipated toxicities from anticancer therapies: Survivors’ perspectives. Support. Care Cancer, 2010, 18(11), 1461-1468.
[15]
Tischer, B.; Huber, R.; Kraemer, M.; Lacouture, M.E. Dermatologic events from EGFR inhibitors: The issue of the missing patient voice. Support. Care Cancer, 2017, 25(2), 651-660.
[16]
Wu, J.; Lacouture, M.E. Pruritus associated with targeted anticancer therapies and their management. Dermatol. Clin., 2018, 36(3), 315-324.
[17]
Ensslin, C.J.; Rosen, A.C.; Wu, S.; Lacouture, M.E. Pruritus in patients treated with targeted cancer therapies: Systematic review and meta-analysis. J. Am. Acad. Dermatol., 2013, 69(5), 708-729.
[18]
Moody, T.W. GRPR (gastrin-releasing peptide receptor). Atlas Genet. Cytogenet. Oncol. Haematol., 2014, 18(10), 711-714.
[19]
Zhou, J.; Chen, J.; Mokotoff, M.; Ball, E.D. Targeting gastrin-releasing peptide receptors for cancer treatment. Anticancer Drugs, 2004, 15(10), 921-927.
[20]
Laukkanen, M.O.; Castellone, M.D. Gastrin-releasing peptide receptor targeting in cancer treatment: Emerging signaling networks and therapeutic applications. Curr. Drug Targets, 2015, 16(14), 1-7.
[21]
Czepielewski, R.S.; Porto, B.N.; Rizzo, L.B.; Roesler, R.; Abujamra, A.L.; Pinto, L.G. Gastrin-releasing peptide receptor (GRPR) mediates chemotaxis in neutrophils. Proc. Natl. Acad. Sci. USA, 2012, 109(2), 547-552.
[22]
Clarimundo, V.S.; Farinon, M.; Pedó, R.T.; Von, T.; Nör, C.; Gulko, P.S. Gastrin-releasing peptide and its receptor increase arthritis fibroblast-like synoviocytes invasiveness through activating the pI3k/akt pathway. Peptides, 2017, 95, 57-61.
[23]
Czepielewski, R.S.; Jaeger, N.; Marques, P.E.; Antunes, M.M.; Rigo, M.M.; Alvarenga, D.M. GRPR antagonist protects from drug-induced liver injury by impairing neutrophil chemotaxis and motility. Eur. J. Immunol., 2017, 47(4), 646-657.
[24]
Roesler, R.; Henriques, J.A.; Schwartsmann, G. Gastrin-releasing
peptide receptor as a molecular target for psychiatric and neurological
disorders. CNS Neurol. Disorders - Drug Targets (Formerly
Curr. Drug Targets),, 2006, 5(2), 197-204.
[25]
Petronilho, F.; Roesler, R.; Schwartsmann, G.; Dal, P.F. Gastrinreleasing
peptide receptor as a molecular target for inflammatory
diseases. Inflamm. Allergy - Drug Targets (Formerly Curr. Drug
Targets – Inflamm. Allergy), 2007, 6(4), 197-200.
[26]
Sun, Y.G.; Chen, Z.F. A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord. Nature, 2007, 448(7154), 700-703.
[27]
Nattkemper, L.A.; Zhao, Z.Q.; Nichols, A.J.; Papoiu, A.D.; Shively, C.A.; Chen, Z.F. Overexpression of the gastrin-releasing peptide in cutaneous nerve fibers and its receptor in the spinal cord in primates with chronic itch. J. Invest. Dermatol., 2013, 133(10), 2489-2492.
[28]
Su, P.Y.; Ko, M.C. The role of central gastrin-releasing peptide and neuromedin b receptors in the modulation of scratching behavior in rats. J. Pharmacol. Experim. Therapeut., 2011, 337(3), 822-829.
[29]
Sukhtankar, D.D.; Ko, M.C. Physiological function of gastrin-releasing peptide and neuromedin B receptors in regulating itch scratching behavior in the spinal cord of mice. PLoS One, 2013, 8(6), e67422.
[30]
Zhao, Z.Q.; Liu, X.Y.; Jeffry, J.; Karunarathne, W.K.; Li, J.L.; Munanairi, A.; Zhou, X.Y.; Li, H.; Sun, Y.G.; Wan, L.; Wu, Z.Y.; Kim, S.; Huo, F.Q.; Mo, P.; Barry, D.M.; Zhang, C.K.; Kim, J.Y.; Gautam, N.; Renner, K.J.; Li, Y.Q.; Chen, Z.F. Descending control of itch transmission by the serotonergic system via 5-ht1a-facilitated GRP-GRPR signaling. Neuron, 2014, 84(4), 821-834.
[31]
Morgat, C.; Macgrogan, G.; Brouste, V.; Vélasco, V.; Sevenet, N.; Bonnefoi, H. Expression of gastrin-releasing peptide receptor (GRPR) in breast cancer and its association with pathological, biological and clinical parameters: a study of 1432 primary tumors. J. Nuclear Med. Off. Publ. Soc. Nuclear Med., 2017, 58(9), 1401-1407.
[32]
Santos, J.; Mesquita, D.; Barrossilva, J.D.; Jerónimo, C.; Henrique, R.; Morais, A. Uncovering potential downstream targets of oncogenic grpr overexpression in prostate carcinomas harboring ets rearrangements. Oncoscience, 2015, 2(5), 497-507.
[33]
Schroeder, R.P.J.; Weerden, W.M.V.; Krenning, E.P.; Bangma, C.H.; Berndsen, S.; Ligt, C.H.G. Gastrin-releasing peptide receptor-based targeting using bombesin analogues is superior to metabolism-based targeting using choline for in vivo imaging of human prostate cancer xenografts. Eur. J. Nucl. Med. Mol. Imaging, 2011, 38(7), 1257-1266.
[34]
Siegfried, J.M.; Krishnamachary, N.; Gaither, D.A.; Gubish, C.; Hunt, J.D.; Shriver, S.P. Evidence for autocrine actions of neuromedin b and gastrin-releasing peptide in non-small cell lung cancer. Pulm. Pharmacol. Ther., 1999, 12(5), 291-302.
[35]
Carroll, R.E.; Ostrovskiy, D.; Lee, S.; Danilkovich, A.; Benya, R.V. Characterization of gastrin-releasing peptide and its receptor aberrantly expressed by human colon cancer cell lines. Mol. Pharmacol., 2000, 58(3), 601-607.
[36]
Pansky, A.; De, W.A.; Fasler-Kan, E.; Boulay, J.L.; Schulz, M.; Ketterer, S. Gastrin releasing peptide-preferring bombesin receptors mediate growth of human renal cell carcinoma. J. Am. Soc. Nephrol., 2000, 11(8), 1409-1418.
[38]
Shirahige, Y.; Cai, R.Z.; Szepeshazi, K.; Halmos, G.; Pinski, J.; Groot, K. (). Inhibitory effect of bombesin/gastrin-releasing peptide (GRP) antagonists RC-3950-ii and RC-3095 on MCF-7 miii human breast cancer xenografts in nude mice. Biomed. Pharmacother., 1994, 48(10), 465-472.
[39]
Halmos, G.; Schally, A.V. Reduction in receptors for bombesin and epidermal growth factor in xenografts of human small-cell lung cancer after treatment with bombesin antagonist RC-3095. Proc. Natl. Acad. Sci. USA, 1997, 94(3), 956-960.
[40]
Yano, T.; Pinski, J.; Szepeshazi, K.; Halmos, G.; Radulovic, S.; Groot, K. Inhibitory effect of bombesin/gastrin-releasing peptide antagonist RC-3095 and luteinizing hormone-releasing hormone antagonist SB-75 on the growth of MCF-7 miii human breast cancer xenografts in athymic nude mice. Cancer, 1994, 73(4), 1229-1238.
[41]
Kahán, Z.; Sun, B.; Schally, A.V.; Arencibia, J.M.; Cai, R.Z.; Groot, K. Inhibition of growth of Mda-Mb-468 estrogen-independent human breast carcinoma by bombesin/gastrin-releasing peptide antagonists Rc-3095 and Rc-3940-ii. Cancer, 2000, 88(6), 1384-1392.
[42]
Bajo, A.M.; Schally, A.V.; Groot, K.; Szepeshazi, K. Bombesin antagonists inhibit proangiogenic factors in human experimental breast cancers. Br. J. Cancer, 2004, 90(1), 245-252.
[43]
Schwartsmann, G.; Dileone, L.P.; Horowitz, M.; Schunemann, D.; Cancella, A.; Pereira, A.S. A phase i trial of the bombesin/gastrin-releasing peptide (BN/GRP) antagonist RC3095 in patients with advanced solid malignancies. Invest. New Drugs, 2006, 24(5), 403-412.
[44]
Jensen, R.T.; Battey, J.F.; Spindel, E.R.; Benya, R.V. International union of pharmacology. LXVIII. mammalian bombesin receptors: Nomenclature, distribution, pharmacology, signaling, and functions in normal and disease states. Pharmacol. Rev., 2008, 60(1), 1-42.
[45]
Carrieri, A.; Lacivita, E.; Belviso, B.D.; Caliandro, R.; Mastrorilli, P.; Gallo, V. Structural determinants in the binding of BB2 receptor ligands: in silico, x-ray and nmr studies in PD176252 analogues. Curr. Top. Med. Chem., 2017, 17(14), 1-12.
[46]
Yao, R.S.; Li, T.T.; Xu, J.; Jiang, L.E.; Ruan, B.F. Design, synthesis and anti-itch activity evaluation of aromatic amino acid derivatives as gastrin-releasing peptide receptor antagonists. Med. Chem., 2012, 8(5), 865-873.
62
5